Company: BSTZ
Filing Date: 2025-03-07
Form Type: N-CSR
Source: 0001193125-25-049659
Chunk: 46

Company: BlackRock Science & Technology Term Trust
Filing Date: 2025-03-07
Form: N-CSR
Chunk 46
---
 the cash collateral from loanedsecurities.                                                                                                                                   |

For purposes of this report, industry and sector sub-classifications may differ from those utilized by the Trust for compliance purposes. 76 2024 BlackRock Annual Report to Shareholders

Schedule of Investments (continued) December 31, 2024 BlackRock Health Sciences Term Trust (BMEZ)

Affiliates Investments in issuers considered to be affiliate(s) of the Trust during the year ended December 31, 2024 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

| Affiliated Issuer                                      | Value at12/31/23 | Purchasesat Cost | Proceedsfrom Sales | NetRealizedGain (Loss) | Change inUnrealizedAppreciation(Depreciation) | Value at12/31/24 | SharesHeld at12/31/24 |     Income | Capital GainDistributionsfromUnderlyingFunds |
| BlackRock Cash Funds: Institutional, SL AgencyShares   |               $— | $10,228,332(a)   | $—                 |                   $560 |                                        $(779) |      $10,228,113 |            10,223,001 | $59,935(b) | $—                                           |
| BlackRock Liquidity Funds, T-Fund, InstitutionalShares |       40,473,813 | 10,647,757(a)    | —                  |                      — |                                             — |       51,121,570 |            51,121,570 |  2,809,759 | —                                            |
| SL Liquidity Series, LLC, Money Market                 
 Series(c)                                              |       12,308,246 | —                | -12,309,250)(a     |                    424 |                                           580 |                — |                     — |  29,603(b) | —                                            |
|                                                        |                  |                  |                    |                   $984 |                                        $(199) |      $61,349,683 |                       | $2,899,297 | $—                                           |

| (a) | Represents net amount purchased (sold).                                                                                                                              |
| (b) | All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of collateral investment fees, and 
 other payments to andfrom borrowers of securities.                                                                                                                   |
| (c) | As of period end,